FDA Approves ALS Treatment Despite Questions About Effectiveness

Author: Yuvi September 30, 2022

FDA Approves ALS Treatment Despite Questions About Effectiveness

The Food and Drug Administration on Thursday approved an experimental treatment for ALS, a severe neurological disorder that causes paralysis and death, despite questions about the therapy’s effectiveness.

The treatment, conceived about a decade ago by two college students, was approved even though analyzes by the FDA’s reviewers concluded there was not yet sufficient evidence that the medication could help patients live longer or slow the rate at which they lose functions like muscle control, speaking or breathing without assistance. Nevertheless, the agency decided to greenlight the drug without waiting two years for results of a large clinical trial, citing data showing the treatment to be safe and the desperation of patients with a disease that often causes death within two-to-five years.

The drug, which has the scientific name AMX0035, will be marketed as Relyvrio.

In a summary memorandum about the drug the FDA wrote that there was “residual uncertainty about the evidence of effectiveness,” but that “given the serious and life-threatening nature of ALS and the substantial unmet need, this level of uncertainty is acceptable in this instance.” The memorandum also said that the benefits outweigh the risks because the treatment is “without any significant safety signals of concern.”

The approval follows an impassioned campaign by patients and advocacy groups. In addition, doctors who treat ALS patients had urged approval in a letter to the FDA and testimony and in testimony before an FDA advisory committee.

“In your difficult job, there’s always going to be a chance of making a mistake; it comes down to which mistake you would rather make,” Dr. Richard Bedlack, director of the ALS clinic at Duke University, testified this month. “To approve AMX0035 and find out in two years that it doesn’t work — I doubt many are going to be very angry because people with ALS got to try something that was safe and appeared promising in 2022.”

But, he added, “Can you imagine the mistake of saying no and then getting confirmatory evidence in two years that this really did work? And realizing all those patients were much more disabled or even dead when they didn’t need to be? I don’t know how you’ll be able to live with yourself if you make that mistake.”

ALS, or amyotrophic lateral sclerosis, also called Lou Gehrig’s disease, is diagnosed in about 6,000 people worldwide each year. There are only two other approved ALS medications in the United States: riluzole, approved in 1995, which can extend survival by several months, and edaravone, approved in 2017, which can slow progression by about 33 percent.

The illness, also called Lou Gehrig’s disease, robs people of their ability to move, speak, eat and ultimately breathe.

Relyvrio was conceived by Justin Klee and Joshua Cohen when they were undergraduate students at Brown University. They proposed that combining taurusodiol, a supplement sometimes used to regulate liver enzymes, and sodium phenylbutyrate, a medication for a pediatric urea disorder, could protect neurons in the brain from damage in diseases like ALS by preventing dysfunction of two structures in cells: mitochondria and the endoplasmic reticulum. They later founded a small Massachusetts company, Amylyx Pharmaceuticals.

As patients learned about the compound, some began obtaining the ingredients on their own from Amazon and other sources. In June, Canada became the first country to approve the treatment, under a special condition requiring Amylyx to later provide better evidence that it worked. Advocacy groups predicted that some American patients would seek it from Canada, where it is marketed as Albrioza, if the FDA didn’t approve it.

Amylyx did not immediately say what price it is considering for the treatment in the United States and has said the price is still being negotiated in Canada.

“Amylyx’s goal is that everyone who is eligible for Relyvrio will have access as quickly and efficiently as possible as we know people with ALS and their families have no time to wait,” the company said in a statement after the FDA announcement.

The medication, a bitter-tasting powder mixed with water and either drunk or ingested through a feeding tube, traveled an unusual and controversial path to approval. The FDA typically requires two persuasive clinical trials, usually Phase 3 trials, which are larger and more extensive than Phase 2 studies. For serious diseases with few treatments, the agency can accept one trial plus additional confirmatory data.

For Relyvrio, the data comes only from one Phase 2 trial in which 137 patients took either the drug or a placebo, plus an extension study that followed some patients after the trial ended when they were knowingly taking the drug.

The Phase 2 trial involved patients considered to have fast-progressing disease. Two-thirds of participants received Relyvrio. Over 24 weeks, they experienced a 25 percent slower decline than participants receiving placebo — declining 2.32 points less on a 48-point ALS scale that rates 12 physical abilities, including walking, speaking, swallowing, dressing, handwriting and breathing.

The open-label extension study involved 90 of those patients, including 34 from the placebo group, who began taking the medication about seven months after those who received it from the beginning. Patients who received the treatment the longest had a median of about 6.5 months more time before being hospitalized, being put on a ventilator or dying, Amylyx reported. Researchers later published another analysis that suggested additional benefit.

The FDA initially recommended that Amylyx not apply for approval until the Phase 3 trial was completed in 2024.

ALS advocacy groups campaigned vehemently to persuade the FDA to reconsider, especially after the agency’s controversial approval last year of the Alzheimer’s drug Aduhelm despite doubts about whether it worked. Soon after, FDA officials began suggesting that Amylyx submit an application for approval using existing data.

In March, a committee of independent advisers to the FDA voted by a narrow margin that the treatment had not yet been shown to be effective, a conclusion also reached by the FDA’s own reviewers. The agency then allowed Amylyx to submit more data and took the unusual step of scheduling a second independent advisory committee meeting on Sept. 7. In a report presented there, agency reviewers said they also considered the new data insufficient.

But Dr. Billy Dunn, director of the FDA’s office of neuroscience, told the advisory committee that “although some might reasonably argue that substantial evidence does not currently exist” to justify approval, the agency should exercise “the broadest flexibility” by also considering the seriousness of the disease and the dearth of available treatments.

Dr. Dunn posed a question to the company: If the treatment received approval now and was shown to be ineffective in the Phase 3 trial, would Amylyx voluntarily withdraw it from the market, saving the agency a lengthy recall process? Mr. Klee said the company would.

That commitment by Amylyx, plus emotional testimony from patients and doctors, persuaded more advisory committee members at the September meeting, where the vote favoring approval was seven to two.

One of those who voted against approval, Dr. Kenneth Fischbeck, a distinguished investigator for the National Institutes of Health, said the company could provide the therapy to patients for free while waiting for better evidence, but “I don’t think it’s met the standard of evidence to allow them to sell the drug ”

Mark Weston, a member of the advisory committee who has ALS, said he was disappointed that the new information the company presented wasn’t stronger. “I was hoping for something more,” he said. But Mr. Weston, who earlier in the meeting named ALS patients who had died since the March hearing, said he voted for approval because “I can’t decouple my thoughts about that from my thoughts about the unmet need.”

That need for treatments was the overwhelming message of patients who testified. “Instead of thinking you are protecting me I want you to recommend approval so that I have the chance to live,” said Brian Wallach, 41, who co-founded “I AM ALS,” an advocacy group, in mostly testimony read by a friend because ALS has been deeply damaged by his ability to speak.

Gregory Canter, one of the clinical trial participants, said “the rate of my functional decline has slowed considerably” since beginning the drug over three years ago.

“ALS is the basement; this starts us up the stairs,” Mr. Canter said. “It won’t get us to the top alone, but each step up is important to point us in the right direction.”

Calanet Balas, president and chief executive of the ALS Association, said in a statement that the FDA decision was “a victory for the entire ALS community, which came together to advocate for early approval of AMX0035.” The association and other advocacy groups met with FDA officials, submitted a petition with over 50,000 signatures and organized a campaign originating over 13,000 emails to the agency.

The ALS Association contributed $2.2 million to the development and study of AMX0035, using money raised through the 2014 Ice Bucket Challenge. Amylyx agreed to use sales of the drug to repay 150 percent of the association’s grant to fund more research.

30 September, 2022, 2:44 am

News Cinema on twitter News Cinema on facebook

Friday, 30th September 2022

More Stories
Kate Middleton pays tribute to Princess Diana as she arrives in the US with Prince William
Cocaine Bear trailer tells true story of predator who ate 70 POUNDS of drug dropped by smugglers
FDA Considering New Approach to Blood Donation by Gay and Bisexual Men
Sen. John Barrasso calls for Biden’s non-binary nuclear was guru Sam Brinton to be ‘terminated’
Wormhole is created inside a quantum computer that ‘teleported’ a message from one side to the other.
Irish Rail worker who is paid £105,000 a year to ‘read the paper’ takes employers to court
Epstein Estate Agrees to Pay More Than $105 Million to US Virgin Islands
Mark Zuckerberg defends the company’s push into the metaverse, where he appeared with a bout of hiccups.
Former Adam Levine yoga instructor says 1992 attack ‘eerily similar’ to University of Idaho slayings
Biden Promises Protections for Nevada’s Spirit Mountain
Fyre Festival fraudster Billy McFarland launches new virtual PYRT festival
Andy Jassy says Amazon will allow the antisemitic film that Kyrie Irving tweeted to remain on sale for now.
Scooter Driver Who Struck and Killed Actress Gets Up to 3 Years
Pamela Rosenkranz Wins the High Line Plinth’s Third Commission
Royal Family news LIVE: William and Kate land in Boston for a three-day visit to the US
Powell says that rates will rise more and remain high ‘for some time.’
San Francisco Considers Allowing Use of Deadly Robots by Police
Life Science, Spacewalk Preps as Station Orbits Higher
NATO Nations Grow More Receptive to US Pleas to Confront China
Prince William and Kate Middleton land in Boston for US trip amid royal race row
New York Police Name a Chief Who Has Faced Internal Discipline
South Africa’s President, Cyril Ramaphosa, Faces Impeachment Hearing
Mother sparks furious debate after waxing her 10-year-old daughter’s face
Outcome in Oath Keepers Trial Could Hold Lessons for Coming Jan. 6 Cases
Elon Musk’s Neuralink to share progress of its brain chip tonight
Sam Brinton: Biden’s nuclear waste guru spoke at a spanking seminar weeks after bag theft
Could Theatrical Movies Shut Out Streamers for the Top Oscars?
17 Public Employees Charged in Schemes to Steal Covid Relief Funds
Deaths From Substance Abuse Rise Sharply Among Older Americans in 2020
White House ‘deeply concerned’ about Paul Whelan
‘Philadelphia is a war zone’: thug strolls up to parking official and shoots him in the head
Indian-origin doc slams ‘racist joke’ at British Curry Awards
Argentina’s World Cup Hangs in the Balance Against Poland
China completes world’s largest solar telescope array with 1.9-mile-wide ring of 313 dishes
Bigg Boss 16 Day 60 Updates: Housemates call Nimrit unfair for favoring Shiv and Soundarya in ranking task
FIFA World Cup 2022: Defending champion France lost to Tunisia
Mariah Carey offers fans opportunity to stay in her apartment BUT the star won’t even be there
House PASSES bill to stop a rail strike on December 9 after Biden asked Congress to step in
In Georgia, Walker’s Pace in the Finish Worries Republican Allies
Hiroshi Miyamura, Given Medal of Honor in Korean War, Dies at 97
Cops kill Illinois man and his grandpa while trying to stop younger man from stabbing his relative
A Resonant Topic in Georgia’s Senate Runoff: Insulin Prices